Adepend 50 Mg Film-Coated Tablets
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Adepend 50 mg filmcoated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each filmcoated tablet contains 50 mg naltrexone hydrochloride.
Excipient: contains 126,755 mg lactose monohydrate.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Filmcoated tablets
Capsule shaped, beige filmcoated tablets with a break-score on each side. The tablet can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Adepend is used as part of a comprehensive programme of treatment against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
4.2 Posology and method of administration
Treatment with naltrexone must not be started before a naloxone provocation test has been performed and the test result is negative.
Naloxone test
- Intravenous administration of 0.2 mg naloxone. If there are no withdrawal symptoms within 30 seconds, another 0.6 mg naloxone i.v. may be administered. During the following 30 minutes, the patient should be monitored continuously to recognize any sign of withdrawal symptoms.
- Subcutaneous administration of 0.8 mg naloxone. The patient should be monitored for withdrawal symptoms for a period of 20 minutes.
In case a withdrawal symptom occurs, naltrexone therapy must not be started.
Confirmation of the test: if there are doubts that the patient is free of opioids, therapy with naltrexone should start 24 hours later. In such a case, the test with 1.6 mg naloxone should be repeated.
Treatment with naltrexone should only be considered for patients who have been free of opioids for at least 7-10 days.
Before starting treatment with naltrexone, this test should be confirmed by a urine test. Thereafter, treatment with 25 mg naltrexone hydrochloride may be initiated.
Higher doses than 150 mg even for only one day may result in an increase in side effects and are therefore not recommended.
Use in adults
The treatment with Adepend 50 mg filmcoated tablets should be started and supervised by a qualified physician.
The recommended dose of naltrexone hydrochloride in adults is 50 mg per day (1 tablet per day).
Use in children and adolescents (<18 years)
Adepend 50 mg filmcoated tablets are not recommended for use in children and adolsecents below 18 in this indication due to a lack of data on safety and efficacy.
Use in elderly
Safe use for the treatment of opiate dependence in the elderly has not been established.
Use in patients with liver and/or kidney diseases
Adepend 50 mg filmcoated tablets are contraindicated for patients with severe liver and/or kidney diseases.
In patients with slight or moderate disorder of liver and/or kidney Adepend 50 mg filmcoated tablets should be applied only with special caution and close-meshed supervision (see 4.4). A dose adaptation should be considered (see 5.2).
Method of administration
Adepend 50 mg filmcoated tablets should be taken with a liquid.
Duration of administration
A common duration of administration cannot be specified as Adepend 50 mg filmcoated tablets are used as concomitant therapy and recovery is individually different for patients addicted to alcohol, even if they are psychologically attended. A treatment duration of at least 3 months is recommended whereas a prolongation might be necessary. Efficacy is proven by controlled studies over a period up to 12 months.
Naltrexone hydrochloride neither causes psychical nor physical addiction. There is no decrease of antagonistic effects during long term treatments.
4.3 Contraindications
- Hypersensitivity to naltrexone hydrochloride or to any of the excipients
- Acute hepatitis
- Severe or acute liver impairment
- Severe renal impairment
- Patients taking opioid-analgesics
- Opioid-addicted patients as acute opioid withdrawal symptoms may occur
- Patients with withdrawal symptoms after administering naloxon hydrochloride (positive result of the naloxone provocation test)
- Positive urine test for opioids.
4.4 Special warnings and precautions for use
In accordance with national guidance the therapy should be initiated and supervised by a physician experienced in the treatment of alcohol-addicted patients.
Due to its hepatotoxic effect, special caution should be taken with the administration of Adepend in patients with acute liver disease or liver impairment.
Naltrexone hydrochloride is metabolised mainly by the liver and mainly eliminated by urine. Therefore patients with liver or renal impairment should be supervised carefully during treatment (see section 4.3. Liver function tests should be conducted before and during therapy.
It is not uncommon that the liver function of alcohol addicts is impaired. In older, obese alcohol addicts, liver function tests have demonstrated abnormal results after administration of higher doses of naltrexone (up to 300 mg/day).
During the treatment, painful conditions should be treated with non-opioid analgesia only.
In opioid-dependent patients, withdrawal symptoms may be caused by Adepend 50 mg filmcoated tablets. These may manifest after 5 minutes and last up to 48 hours. The treatment should be symptomatic and may include administration of opioids.
It is recommended to perform a naloxone provocation test for opioids. Withdrawal symptoms caused by naloxone hydrochloride are of shorter duration than those precipitated by Adepend 50 mg filmcoated tablets.
The naloxone provocation test should be made neither in patients with clinically prominent withdrawal symptoms nor in patients with a positive urine test for opioids.
Patients must be warned against the use of high doses of opioids to neutralize the blockade as this might result in acute and possibly fatal overdosage of opioids as soon as the effect of naltrexone has ceased. High-dose opioid intake, concomitant with naltrexone treatment, can lead to life-threatening opioid poisoning from respiratory and circulatory impairment.
Patients might be more sensitive to opioid containing medicines after treatment with Adepend 50 mg filmcoated tablets.
Naltrexone may cause a transient increase in the diastolic blood pressure followed by decrease in body temperature and heart rate.
Patients must be warned against concomitant use of opioids (e.g. opioid containing cough medication, opioid containing medication for symptomatic treatment of common cold or opioid containing medication for diarrhea etc.) during treatment with Adepend 50 mg filmcoated tablets.
If the patient treated with Adepend 50 mg filmcoated tablets needs opioid treatment,
e.g. opioid analgesia or anesthesia in emergency situations, the dose needed may be higher than normal to reach the same therapeutic effect. In these cases, respiratory depression and circulatory disturbance will be more profound and longer lasting. Symptoms related to release of histamine (e.g. face swelling, itching, erythema, diaphoresis and other skin and mucocutaneous manifestations) can occur more easily. The patient requires specific attention and supervision by health care personnel in a medical unit.
The increased suicidal risk in drug addicts with or without accompanying depression is not reduced by the intake of Adepend 50 mg filmcoated tablets.
Lactose: Patients with the rare hereditary galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
At the moment, there is only limited clinical experience and experimental data on the effect of naltrexone on the pharmacokinetics of other substances. Concomitant treatment with naltrexone and other medicinal products should be conducted with caution and should be followed carefully.
No studies for interactions have been performed.
One case of lethargy and somnolence has been reported after concomitant use of naltrexone and thioridazine.
In vitro studies have shown that neither naltrexone hydrochlorid nor its active metabolite 6-beta-naltrexol is metabolised by human cytochrom P450 enzymes. Therefore it is unlikely that the pharmacokinetics of Adepend 50 mg filmcoated tablets is affected by cytochrom P450 enzyme inhibiting or inducing drugs:
Sedatives: Opioid derivatives (analgesics, antitussive medicines, drug substitution), neuroleptics, barbiturates, benzodiazepines, anxiolytics which are not benzodiazepines (e.g. meprobamat), hypnotics, sedative antidepressants (amitryptiline, doxepine, mianserin, trimipramine), sedative antihistamines H1, antihypertensive medicine, baclofen, thalidomide.
Patients might be more sensitive to opioid containing medicines after treatment with Adepend 50 mg filmcoated tablets.
Concomitant use of opioid analgesics acting as agonists, agonist-antagonist acting opioids or opioids in the substitution therapy is not recommended.
Concomitant administration of barbiturates and benzodiazepines may be considered.
So far, no interaction between cocaine and naltrexone hydrochloride has been described.
Data from a safety and tolerability study of co-administration of naltrexone with acamprosate in non-treatment seeking, alcohol dependent individuals showed that naltrexone administration significantly increased the acamprosate plasma level. Interaction with other psychopharmacological agents (e.g. disulfirame, amitryptiline, doxepine, lithium, clozapine, benzodiazepines) have not been investigated.
Currently, interactions between naltrexone and alcohol are not known.
For interactions with opioid containing drugs, please see 4.4.
4.6 Pregnancy and lactation
Pregnancy:
There are no clinical data about the use of naltrexone hydrochloride during pregnancy. However, data from animal studies showed reproductive toxicity (see 5.3). These data are not sufficient for showing clinical relevance. The possible risk for humans is not known.
Therefore, Adepend 50 mg filmcoated tablets should only be given to pregnant women on clear indication and after tight consideration that potential benefits outweigh the possible risk.
The application of naltrexone in pregnant alcohol dependent patients using opioids as long-term therapy or substitution therapy or in opioid dependent pregnant women holds the risk of acute withdrawal symptoms with possibly serious effects on the mother and foetus (see section 4.4). Treatment with naltrexone must be interrupted if opioid containing analgesics are prescribed (see section 4.5).
Lactation:
There are no clinical data about the use of naltrexone hydrochloride during breast feeding. It is unknown whether naltrexone hydrochloride or 6-beta-naltexol is excreted in human breast milk. During treatment breast feeding is not recommended.
4.7 Effects on ability to drive and use machines
Adepend 50 mg filmcoated tablets may influence psychological and physical abilities and, therefore, dangerous responsibilities like driving vehicles or using machines should be avoided.
4.8 Undesirable effects
The following undesirable effects are classified according to system organ class and frequency:
Very common (> 1/10)
Common (>1/100 to < 1/10)
Uncommon (>1/1.000 to < 1/100)
Rare (> 1/10.000 to < 1/1.000)
Very rare (< 1/10.000)
not known (cannot be estimated from the available data)
Infections and infestations
Uncommon: oral herpes, athlete’s foot
Blood and lymphatic system disorders
Uncommon: lymphadenopathy Rare: idiopathic thrombopenia
Metabolism and nutrition disorders
Common: loss of appetite
Psychiatric disorders
Very common: nervousness, anxiety, sleep disorders, insomnia Common: irritability, mental disorder
Uncommon: hallucination, confusion, despondency, depression, paranoia, disorientation, nightmares, restlessness, abnormal dreams Rare: suicidal ideation, attempted suicide
Nervous system disorders
Very common: headache Common: fatigue, dizziness, stupor Uncommon: tremor Rare: speech disorders
Eye disorders
Common: increased tear secretion (lacrimation)
Uncommon: vision disorders, irritation and swelling of the eye, photophobia, eye pain or tiredness, colour asthenopia
Ear and labyrinth disorders
Uncommon: ear disorders, ear pain, tinnitus, vertigo
Cardiac disorders
Common: tachycardia, heart palpitation, anomalies in the ECG
Vascular disorders
Uncommon: oedema, hypertension, blood pressure changes, flushing Rare: syncope
Respiratory, thoracic and mediastinal disorders
Common: pain in the chest, dyspnoea
Uncommon: nasal congestion, nasal disorders, rinorrhoea, sneezing, oropharyngeal disorders, increased sputum, sinus disorders, dysphonia, coughing, yawning
Gastrointestinal disorders
Very common: abdominal pain, abdominal cramps, nausea, emesis Common: diarrhoea, constipation
Uncommon: flatulence, haemorrhoids, ulcus, mouth dryness Hepatobiliary disorders
Uncommon: hepatic disorders, increased bilirubin levels, hepatitis (During treatment, increase of transaminases is possible. After discontinuing the intake of Adepend, transaminases decrease to the original levels within some weeks.)
Skin and subcutaneous tissue disorders
Common: dermatitis, pruritus, rash Uncommon: seborrhea, acne, alopecia
Musculoskeleteal and connective tissue disorders
Very common: joint and muscle pain Uncommon: groin pain Very rare: rhabdomyolysis
Renal and urinary disorders
Common: urinary retention
Uncommon: pollakisuria, dysuria
Reproductive system and breast disorders
Common: delayed ejaculation, decreased potency, libido disorders
General disorders and administration site conditions
Very common: feebleness
Common: thirst, increased energy, weight loss, weight gain, fever, pain, sensation of cold in extremities, hot flashes
4.9 Overdose
Symptoms
There is limited experience with overdose of naltrexone hydrochloride. There was no evidence of toxicity in volunteers receiving 800 mg naltrexone hydrochloride per day for one week.
Treatment
In case of overdose, patients should be closely monitored and treated symptomatically.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Drugs used in alcohol dependence ATC code: N07BB04
Naltrexone hydrochloride is an orally used, long acting specific opioid antagonist. Naltrexone hydrochloride binds competitively to receptors which are located in the central and peripheral nervous system and hence blocks the access for exogenously administered opioids.
Treatment with Adepend 50 mg filmcoated tablets does not lead to physical or psychological dependence. No tolerance for the opioid antagonising effect is seen.
The mechanism of action of naltrexone hydrochloride is not completely elucidated. An interaction with the endogenous opioid system is assumed. Alcohol consumption in humans has been hypothesised to
reinforce an alcohol-induced stimulation of the endogenous opioid system.
A therapy with Adepend 50 mg filmcoated tablets is a non-aversive therapy and does not cause reactions when alcohol is ingested. Therefore there are also no disulfiram-like reactions.
The main effect of the treatment with Adepend 50 mg filmcoated tablets seems to be a reduction of the risk of a full relapse after having consumed a limited amount of
alcohol. This gives the patient the possibility to escape a full relapse with complete loss of control because of decreased stimulation.
Naltrexone hydrochloride reduces the desire for alcohol (“craving”) during abstinence and after alcohol ingestion. The reduction of desire for alcohol lowers the risk of a full relapse of abstinent and non-abstinent patients.
5.2 Pharmacokinetic properties
Absorption
After oral administration naltrexone hydrochloride is rapidly and completely absorbed from the gastrointestinal tract. Peak plasma concentration is reached within one hour.
Distribution
Plasmaprotein-binding is 21%. The steady-state plasma-level is 8.55 mg/ml. Metabolism
Metabolism takes place mainly by a first-pass effect in the liver.Naltrexone hydrochloride is basically hydroxylated to the main active metabolite 6-beta-naltrexol and, to a lesser extent, to 2-hydroxy-3-methoxy-6-beta-naltrexol.
Excretion
The substance is excreted primarily renally. About 60 % of the perorally given dose is excreted within 48 hours as glucuronidised 6-beta-naltrexol and naltrexone hydrochloride. The plasma-half-life of naltrexone hydrochloride is approximately 4 hours. The plasma-half-life of 6-beta-naltrexol is 13 hours.
Five to ten times higher plasma concentrations of naltrexone hydrochloride have been reported in cirrhotic patients.
5.3 Preclinical safety data
Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. However, there is some evidence on hepatotoxicity with increasing dose. Reversible increases of liver enzymes have been found in patients treated with therapeutic or higher doses (see section 4.4 and 4.8).
Naltrexone hydrochloride (100 mg/kg/day, approximately 140 times the human therapeutic dose) caused a significant increase of pseudo-pregnancy in rats. A decrease of the pregnancy rate of mated female rats also occurred. The relevance of these observations to human fertility is not known.
Naltrexone hydrochloride has been shown to have an embryotoxic effect in rat and rabbit when given in doses approximately 140 times the human therapeutic dose. This effect was demonstrated in rats dosed with 100 mg/kg/day naltrexone hydrochloride prior to and throughout gestation, and rabbits treated with 60 mg/kg/day naltrexone hydrochloride during the period of organogenesis.
PHARMACEUTICAL PARTICULARS
6
6.1 List of excipients
Tablet core:
Lactose monohydrate Powered cellulose Crospovidone Microcrystalline cellulose Silica, colloidal anhydrous Magnesium stearate
Film-coat:
Lactose monohydrate Hypromellose Titanium dioxide (E 171)
Macrogol 4000
Black ferric oxide (E 172)
Red ferric oxide (E 172)
Yellow ferric oxide (E 172)
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
4 years.
6.4 Special precautions for storage
Do not store above 25 °C.
Store in the original package in order to protect from light.
6.5 Nature and contents of container
7, 14 and 28 tablets in PVC/PVDC/Aluminium blister packed in a carton. Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
7 MARKETING AUTHORISATION HOLDER
Orpha-Devel Handels und Vertriebs GmbH Wintergasse 85/1B A-3002 Purkersdorf Austria
8 MARKETING AUTHORISATION NUMBER(S)
PL 30414/0013
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
22/12/2011
10 DATE OF REVISION OF THE TEXT
16/04/2013